268 related articles for article (PubMed ID: 20028780)
41. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
Maus CE; Plikaytis BB; Shinnick TM
Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
[TBL] [Abstract][Full Text] [Related]
42. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA
Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820
[TBL] [Abstract][Full Text] [Related]
43. Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa.
Schilke K; Weyer K; Bretzel G; Amthor B; Brandt J; Sticht-Groh V; Fourie PB; Haas WH
Int J Tuberc Lung Dis; 1999 Jul; 3(7):620-6. PubMed ID: 10423225
[TBL] [Abstract][Full Text] [Related]
44. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
Migliori GB; D'Arcy Richardson M; Sotgiu G; Lange C
Clin Chest Med; 2009 Dec; 30(4):637-65, vii. PubMed ID: 19925959
[TBL] [Abstract][Full Text] [Related]
45. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa.
Andrews JR; Gandhi NR; Moodley P; Shah NS; Bohlken L; Moll AP; Pillay M; Friedland G; Sturm AW;
J Infect Dis; 2008 Dec; 198(11):1582-9. PubMed ID: 18847372
[TBL] [Abstract][Full Text] [Related]
46. [New era in molecular epidemiology of tuberculosis in Japan].
Takashima T; Iwamoto T
Kekkaku; 2006 Nov; 81(11):693-707. PubMed ID: 17154049
[TBL] [Abstract][Full Text] [Related]
47. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
48. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
49. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
[TBL] [Abstract][Full Text] [Related]
50. Characterization of the genetic diversity of extensively-drug resistant Mycobacterium tuberculosis clinical isolates from pulmonary tuberculosis patients in Peru.
Cáceres O; Rastogi N; Bartra C; Couvin D; Galarza M; Asencios L; Mendoza-Ticona A
PLoS One; 2014; 9(12):e112789. PubMed ID: 25489950
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.
Hu Y; Hoffner S; Wu L; Zhao Q; Jiang W; Xu B
Antimicrob Agents Chemother; 2013 Aug; 57(8):3857-63. PubMed ID: 23733477
[TBL] [Abstract][Full Text] [Related]
52. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Khanna A; Raj VS; Tarai B; Sood R; Pareek PK; Upadhyay DJ; Sharma P; Rattan A; Saini KS; Singh H
Antimicrob Agents Chemother; 2010 Nov; 54(11):4789-93. PubMed ID: 20713679
[TBL] [Abstract][Full Text] [Related]
53. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China.
Sun Z; Chao Y; Zhang X; Zhang J; Li Y; Qiu Y; Liu Y; Nie L; Guo A; Li C
J Clin Microbiol; 2008 Dec; 46(12):4075-7. PubMed ID: 18945837
[TBL] [Abstract][Full Text] [Related]
54. First molecular epidemiological study of tuberculosis in Benin.
Affolabi D; Anyo G; Faïhun F; Sanoussi N; Shamputa IC; Rigouts L; Kestens L; Anagonou S; Portaels F
Int J Tuberc Lung Dis; 2009 Mar; 13(3):317-22. PubMed ID: 19275790
[TBL] [Abstract][Full Text] [Related]
55. Molecular characteristics of strains of the cameroon family, the major group of Mycobacterium tuberculosis in a country with a high prevalence of tuberculosis.
Niobe-Eyangoh SN; Kuaban C; Sorlin P; Thonnon J; Vincent V; Gutierrez MC
J Clin Microbiol; 2004 Nov; 42(11):5029-35. PubMed ID: 15528691
[TBL] [Abstract][Full Text] [Related]
56. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
57. [Investigation of rpsL and rrs gene region mutations in streptomycin resistant Mycobacterium tuberculosis complex isolates].
Ulger M; Aslan G; Emekdaş G; Tezcan S; Serin MS
Mikrobiyol Bul; 2009 Jan; 43(1):115-20. PubMed ID: 19334387
[TBL] [Abstract][Full Text] [Related]
58. Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China.
Hu Y; Mathema B; Zhao Q; Chen L; Lu W; Wang W; Kreiswirth B; Xu B
Clin Microbiol Infect; 2015 Dec; 21(12):1093.e9-1093.e18. PubMed ID: 26348262
[TBL] [Abstract][Full Text] [Related]
59. Investigation and control of a large outbreak of multi-drug resistant tuberculosis at a central Lisbon hospital.
Hannan MM; Peres H; Maltez F; Hayward AC; Machado J; Morgado A; Proenca R; Nelson MR; Bico J; Young DB; Gazzard BS
J Hosp Infect; 2001 Feb; 47(2):91-7. PubMed ID: 11170771
[TBL] [Abstract][Full Text] [Related]
60. Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant
Li Q; Gao H; Zhang Z; Tian Y; Liu T; Wang Y; Lu J; Liu Y; Dai E
Front Microbiol; 2019; 10():1838. PubMed ID: 31447823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
